Oncolytics Biotech announced results examining percent overall tumour shrinkage data from its U.S. Phase 2 clinical trial in patients with squamous cell carcinoma of the lung, or SCCLC, using intravenous administration of Reolysin in combination with carboplatin and paclitaxel. The analysis examined percent best overall tumour changes between pre-treatment and up to six treatment cycles. Of 20 evaluable patients, 19 exhibited overall tumour shrinkage.
- Pharmaceuticals & Drug Trials
- squamous cell carcinoma